0.377
Bioatla Inc stock is traded at $0.377, with a volume of 660.17K.
It is down -5.70% in the last 24 hours and down -4.56% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3998
Open:
$0.3953
24h Volume:
660.17K
Relative Volume:
1.09
Market Cap:
$22.02M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1456
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+1.73%
1M Performance:
-4.56%
6M Performance:
-24.54%
1Y Performance:
-77.95%
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BCAB
Bioatla Inc
|
0.377 | 19.94M | 0 | -123.46M | -104.11M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-21-22 | Initiated | H.C. Wainwright | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Jun-28-21 | Initiated | ROTH Capital | Buy |
May-05-21 | Resumed | Credit Suisse | Outperform |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Jan-11-21 | Initiated | BTIG Research | Buy |
Jan-11-21 | Initiated | Credit Suisse | Outperform |
Jan-11-21 | Initiated | JP Morgan | Overweight |
Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional
What drives BioAtla Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
BioAtla Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister
Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser
What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times
What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser
Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance
BioAtla Approves 2025 Corporate Bonus Plan - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):